Literature DB >> 8819258

Magnesium inhibits platelet activity--an in vitro study.

H B Ravn1, H Vissinger, S D Kristensen, S E Husted.   

Abstract

The in vitro effect of magnesium (Mg) on platelet aggregation and platelet release function was evaluated in healthy volunteers. Platelet aggregation was induced with collagen, ADP, or thrombin after incubation of the sample with saline or increasing concentrations of magnesium sulphate (MgSO4) (0.5-8.0 mM). Mg showed a dose-dependent inhibition of platelet aggregation in whole blood, platelet rich plasma and washed platelets. An antiaggregatory effect was also present with low Mg concentrations. Statistically significant inhibition of the mean aggregation response was obtained in 83% of the different media and agonists tested following the addition of 1.0 mM Mg. The remaining 17% were significantly inhibited with the addition of 2.0 mM Mg. The platelet synthesis of thromboxane A2 and release of beta-thromboglobulin were also inhibited by Mg, in a dose-dependent manner. In order to evaluate if any of these effects were modified by conventional antithrombotic treatment with low-dose acetylsalicylic acid (ASA), volunteers were asked to meet on two consecutive days. On day 2 the participants were given 300 mg ASA orally, one hour prior to blood sampling. The Mg mediated effects were present independent of this pretreatment with ASA. Following stimulation with collagen a synergistic effect of Mg and ASA was demonstrated on platelet aggregation. The platelet inhibiting effect demonstrated in this study may in part explain the beneficial effect of Mg infusion in some patients with acute myocardial infarction. The effect of Mg infusion, given alone or administered simultaneously with ASA, should also be evaluated in other arterial thrombotic disease states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819258

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Maternal levels of prostacyclin, thromboxane, ICAM, and VCAM in normal and preeclamptic pregnancies.

Authors:  David F Lewis; Bernard J Canzoneri; Yang Gu; Shuang Zhao; Yuping Wang
Journal:  Am J Reprod Immunol       Date:  2010-12       Impact factor: 3.886

2.  Prostacyclin and thromboxane levels in women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods.

Authors:  Yuping Wang; Yanping Zhang; Bernard J Canzoneri; Yang Gu; Lisa Philibert; David F Lewis
Journal:  Hypertens Pregnancy       Date:  2008       Impact factor: 2.108

3.  Biphasic responses of human vascular smooth muscle cells to magnesium ion.

Authors:  Jun Ma; Nan Zhao; Donghui Zhu
Journal:  J Biomed Mater Res A       Date:  2015-10-07       Impact factor: 4.396

4.  Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease.

Authors:  Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Elizabeth Selvin; Josef Coresh; Wen Hong Linda Kao
Journal:  Kidney Int       Date:  2014-10-01       Impact factor: 10.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.